{
    "ASSERTIONS": {
        "id": 760,
        "context": null,
        "description": "Results from the METEOR trial (n=658) suggest that the MET expression level might not affect treatment outcomes with cabozantinib in this patient population.",
        "disease": {
            "name": "Renal Clear Cell Carcinoma",
            "oncotree_code": "RCC",
            "oncotree_term": "Renal Clear Cell Carcinoma"
        },
        "therapy_name": "Cabozantinib",
        "therapy_type": "Targeted therapy",
        "clinical_significance": null,
        "predictive_implication": "Inferential",
        "favorable_prognosis": null,
        "created_on": "11/04/21",
        "last_updated": "2019-08-12",
        "submitted_by": "breardon@broadinstitute.org",
        "validated": true,
        "source_ids": 228,
        "variant": {
            "id": 758,
            "cytoband": null,
            "direction": "Amplification",
            "feature_type": "copy_number",
            "gene": "MET",
            "feature": "MET Amplification"
        }
    },
    "SOURCES": {
        "id": 228,
        "type": "Journal",
        "doi": "10.1056/NEJMoa1510016",
        "nct": "NCT01865747",
        "pmid": 26406150,
        "url": "https://doi.org/10.1056/NEJMoa1510016",
        "citation": "Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-23."
    },
    "VARIANTS": {
        "id": 758,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MET",
        "feature": "MET Amplification"
    }
}